Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2)

The COVID-19 Omicron variant has already made its way across the globe and has raised new challenges for the scientists are diligently pursuing their research throughout the pandemic. Therefore, to support the scientific community, we are glad to announce the launch of Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit from our partner BPS Biosciences.

The COVID-19 pandemic is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The Spike glycoprotein is expressed on the surface of the virus as a trimer. Each Spike protein consists of two subunits, S1 and S2, and the S1 subunit contains the receptor-binding domain (RBD) which recognizes and attaches to the ACE2 receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. SARS-CoV-2 Variant B.1.1.529, also known as Omicron variant, was originally discovered in South Africa.

Drugs targeting the interaction between SARS-CoV-2 Spike protein and human ACE2 may offer some protection against viral infection. The SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein in this kit consists of the RBD region of the S1 protein, which includes the ACE2 binding site.

The Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of the interaction between the Omicron variant SARS-CoV-2 Spike RBD and human ACE2.